0001493152-26-015662
SEC filingMAIA Biotechnology announced that net proceeds from its recent $33 million public stock offering are expected to fully fund the ongoing pivotal Phase 3 trial of ateganosine for third-line NSCLC.
MAIA Biotechnology's $33 million public offering of common stock in March 2026 provides critical funding to sustain its lead program through the pivotal THIO-104 Phase 3 trial completion. The strong participation from healthcare investors and existing shareholders signals confidence in ateganosine's clinical momentum and commercial potential in third-line NSCLC, where chemotherapy remains the standard. Ateganosine, a first-in-class telomere-targeting agent with dual mechanism to disrupt cancer cell telomeres and activate immune responses, has FDA Fast Track designation, accelerating development. The global, multicenter THIO-104 trial randomizes up to 300 CPI-resistant patients 1:1 to ateganosine sequenced with checkpoint inhibitors versus chemotherapy, with overall survival as the primary endpoint. CEO Vlad Vitoc highlighted statistical assessments indicating high technical success probability if Phase 3 aligns with Phase 2 results, and interim data next year could enable FDA discussions for early approval. This funding milestone de-risks execution, positioning MAIA to advance toward potential commercialization in NSCLC.